

**From:** [OC GCP Questions](#)  
**To:** [REDACTED]  
**Subject:** Regarding Quality Assurance  
**Date:** Friday, June 26, 2015 2:05:36 PM

---

Good morning –

Your questions cannot be specifically answered as it depends on the clinical trial, the investigational product and the sponsor requirements. Please see a few FDA guidance documents that might be helpful to you.

<http://www.fda.gov/downloads/Drugs/Guidances/ucm070305.pdf>

<http://www.fda.gov/downloads/Drugs/.../Guidances/UCM070337.pdf>

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf>

Please also see footnote 10 on page 4. It references auditing of clinical trials.

[Compliance Policy Guides > CPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections](#)

Kind regards,

Doreen M. Kezer, MSN  
Senior Health Policy Analyst  
Office of Good Clinical Practice  
Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

---

**From:** [REDACTED]  
**Sent:** Friday, June 26, 2015 5:27 AM  
**To:** OC GCP Questions  
**Subject:** Regarding Quality Assurance

Dear Sir,

Greetings!

I am in process evolving our clinical quality control and assurance program and require guidance on following questions:

1. Whom shall QA and QC function report? Is it head of clinical R&D or head of institute?
2. What percentage of clinical study data should be audited for Quality assurance?
3. Can one open the old clinical study reports and subject to intense quality assurance program?, if yes, how to treat the discrepancies, if any in the CSR.

Best regards,

[REDACTED]